Esperion Therapeutics (NASDAQ:ESPR) Now Covered by The Goldman Sachs Group

The Goldman Sachs Group began coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note issued to investors on Wednesday morning, MarketBeat.com reports. The brokerage issued a neutral rating and a $4.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also weighed in on ESPR. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a research report on Tuesday. They issued an “overweight” rating and a $8.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and an average price target of $7.30.

Esperion Therapeutics Trading Up 1.4 %

Shares of ESPR stock traded up $0.03 on Wednesday, reaching $2.19. The company had a trading volume of 1,101,253 shares, compared to its average volume of 6,366,823. The company has a 50-day moving average of $2.41 and a 200-day moving average of $2.22. Esperion Therapeutics has a 12 month low of $1.58 and a 12 month high of $3.94. The stock has a market cap of $431.51 million, a PE ratio of -3.42 and a beta of 1.01.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of ESPR. SG Americas Securities LLC lifted its position in shares of Esperion Therapeutics by 45.3% in the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 11,658 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 555,382 shares in the last quarter. Summit Financial LLC boosted its stake in shares of Esperion Therapeutics by 26.4% during the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 6,823 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Esperion Therapeutics by 6,560.6% in the 2nd quarter. Rhumbline Advisers now owns 252,038 shares of the biopharmaceutical company’s stock valued at $560,000 after acquiring an additional 248,254 shares in the last quarter. Finally, Midland Wealth Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at about $133,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.